Enhanced anti-cancer activities of some derivatives of titanocene dichloride.
The compounds (eta5-C5H5)2TiCl2 (I), currently undergoing phase II trials, (eta5-C5H5)(eta5-C5H4CO2Me)TiCl2 (II) and C5H4CO2Me)2TiCl2 (III) are assessed for their efficacies against a small lung cancer cell line. It is found that the introduction of the electron withdrawing carbomethoxy group into the cyclopentadienyl rings increases the effectiveness of this class of drugs, such that III compares favorably with the well known cisplatin.
Boyles
J R
JR
Department of Chemistry, Queen's University, Kingston, Canada.
Bair
M C
MC
Campling
B G
BG
Jain
N
N
D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D009942:Organometallic Compounds / Q000737:chemistry / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; C020528:titanocene dichloride